Danish Pharma Stock News

Vestas Wind Systems (CPSE:VWS) is back in focus after securing a 70 MW order for the Strazhitsa wind project in Bulgaria, paired with a long term service deal and fresh governance updates. See our latest analysis for Vestas Wind Systems. The recent 70 MW Bulgarian order, dividend approval and board changes arrive as Vestas posts a 27.0% 1 month share price return and a very large 1 year total shareholder return. However, the 5 year total shareholder return of a 15.57% decline shows that...

Q1 2026 earnings snapshot and how the story might be shifting Tryg (CPSE:TRYG) has set the stage for its Q1 2026 update with Q4 2025 revenue of about DKK 10.9 billion and Basic EPS of DKK 2.06, underpinned by trailing twelve month revenue of roughly DKK 43.0 billion and EPS of DKK 8.83. Over recent quarters, the company has seen revenue move from DKK 9.94 billion in Q4 2024 to around DKK 10.9 billion in Q4 2025, while quarterly EPS shifted from DKK 1.22 to DKK 2.06. This gives investors a...

If you are wondering whether Genmab shares are offering fair value at current levels or if the price is getting ahead of itself, this article breaks down what the numbers say about the stock. Over the past week Genmab is up 2.9%. Over the last month it is up 7.3%. Year to date the return sits at an 8.3% decline, while the 1 year return is 42.5%. Taken together, this gives a mixed picture for anyone eyeing the recent share price. These moves sit against a backdrop where investors are weighing...

Novo Nordisk recently announced a wide-ranging partnership with OpenAI to integrate advanced AI across drug discovery, manufacturing, supply chain and commercial operations, with pilot projects underway and full roll-out targeted by the end of 2026 under strict data governance and human oversight. This collaboration could reshape how Novo Nordisk develops and delivers treatments by using AI to interpret complex datasets, shorten research timelines and support more efficient global operations...

Alm. Brand (CPSE:ALMB) has drawn attention after extending its collaboration with Ondo InsurTech’s LeakBot. The insurer plans to offer the leak detection device to up to 160,000 homeowners across its Danish insurance brands. See our latest analysis for Alm. Brand. The expanded LeakBot rollout and recent AGM decisions come after a weaker short term patch, with a 90 day share price return of 16.44% decline and year to date share price return of 17.74% decline, set against a 1 year total...

TORM plc ( CPH:TRMD A ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

Danske Bank (CPSE:DANSKE) has drawn renewed attention after recent share price moves, with the stock last closing at DKK 336. For investors, the key question is how current fundamentals align with that valuation. See our latest analysis for Danske Bank. The recent 1-day share price return of 2.4% and 7-day share price return of 8.0% point to short term momentum, while the 1-year total shareholder return of 68.3% and 5-year total shareholder return above 300% show a strong longer term payoff...

Understanding ALK-Abelló After Recent Performance Shifts ALK-Abelló (CPSE:ALK B) has drawn attention after a mixed stretch in its share performance, with a 1 day pullback, a positive month, but weaker returns over the past 3 months and year to date. See our latest analysis for ALK-Abelló. At the current share price of DKK215.0, ALK-Abelló has seen short term share price momentum fade with a 90 day share price return of a 6.2% decline. Longer term total shareholder returns of 47.77% over 1...

Recent share performance and business snapshot Novo Nordisk (CPSE:NOVO B) has been under pressure, with the share price showing a 1 day decline of about 1% and negative returns over the past week, month and past 3 months. Despite this weaker recent performance, the company reports annual revenue of DKK 309.1b and net income of DKK 102.4b. Most of this comes from its Diabetes and Obesity Care segment, supported by a smaller Rare Disease business. See our latest analysis for Novo Nordisk. At...

As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.

Readers hoping to buy ISS A/S ( CPH:ISS ) for its dividend will need to make their move shortly, as the stock is about...

Readers hoping to buy Scandinavian Tobacco Group A/S ( CPH:STG ) for its dividend will need to make their move shortly...

In early April 2026, NKT reached a key milestone with the past launch of the NKT Eleonora’s hull at VARD’s Romanian shipyard, a new cable-laying vessel featuring advanced dynamic positioning and a loading capacity of 23,000 tons of cable. The ship’s methanol-compatible dual-fuel engines highlight how NKT is integrating lower-emission technology into heavy offshore assets that support future grid interconnections. We’ll now examine how the NKT Eleonora’s methanol-ready, high-capacity design...

Aktieselskabet Schouw & Co. ( CPH:SCHO ) is about to trade ex-dividend in the next 4 days. The ex-dividend date...

Capital reduction and what it means for Pandora shareholders Pandora (CPSE:PNDORA) has confirmed a reduction in its share capital after cancelling 4,000,000 treasury shares of DKK 1, an action now completed following approval at the recent Annual General Meeting. This capital reduction, registered with the Danish Business Authority after a 4 week notification period without objections, trims the number of shares outstanding and may influence how investors view Pandora’s capital structure and...

Why the NKT Eleonora hull launch matters for NKT (CPSE:NKT) The hull launch of the NKT Eleonora at VARD's Romanian shipyard puts fresh attention on NKT (CPSE:NKT), as investors consider how this high-capacity, lower-emission cable vessel could influence the group’s position in power cable projects. See our latest analysis for NKT. The recent hull launch comes as NKT's share price stands at DKK929.0, with a 30-day share price return of 15.26% and a 1-year total shareholder return of 97.07%,...

What recent returns say about A.P. Møller - Mærsk (CPSE:MAERSK B) A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed share price moves recently, with a 2.5% decline over the past day and a 1.1% slip over the past week, as well as a 4.8% gain over the past 3 months. See our latest analysis for A.P. Møller - Mærsk. Zooming out, the recent share price softness contrasts with a much stronger picture over longer periods, with a 7.7% year to date share price return alongside a 60.2% 1 year total...

Novo Nordisk (CPSE:NOVO B) released head to head ORION trial data showing oral semaglutide produced greater weight loss and better tolerability than Eli Lilly’s new orforglipron pill. Eli Lilly has started the U.S. launch of its oral obesity pill under the brand name Foundayo, setting up direct competition in the oral GLP-1 market. The European Medicines Agency approved more flexible cold chain rules for Wegovy, changing how the drug can be stored and handled. In India, rapid growth of...

Wondering whether Danske Bank's current share price reflects its underlying value, or if the market is missing something you can spot? The stock last closed at kr322.9, with returns of 1.2% over 7 days, a 0.8% decline over 30 days, 1.1% year to date, 73.6% over 1 year, 200.0% over 3 years and 261.7% over 5 years, which gives plenty of price action for investors to think about. Those moves sit against a backdrop of ongoing coverage of Danske Bank's business, regulation and broader sector...

Wondering whether Ringkjøbing Landbobank is fairly priced or starting to look interesting at current levels? This article walks through what the numbers are saying about the stock’s value. The shares last closed at DKK 1,574, with returns of 0.6% over 7 days, a 1.4% decline over 30 days, 1.9% year to date, 44.6% over 1 year, 62.5% over 3 years and 163.6% over 5 years. These figures may influence how you think about upside and risk today. Recent coverage around Ringkjøbing Landbobank has...

CK Hutchison has taken A.P. Møller - Mærsk to arbitration in London over Panama port assets after APM Terminals was appointed interim operator, adding legal complexity to an already politically sensitive dispute involving Panama, the US and China. At the same time, Maersk is confronting fresh uncertainty in the Strait of Hormuz as Iran seeks cryptocurrency toll payments during a temporary ceasefire, underlining how geopolitical and regulatory shifts can directly affect the company’s global...

As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending the week up 3.92% in local currency terms. This positive sentiment is supported by hopes for a shorter-lived conflict and is reflected in gains across major stock indexes like Germany's DAX and Italy's FTSE MIB. In this environment, identifying promising stocks involves looking for companies with strong fundamentals that can...

Why FLSmidth (CPSE:FLS) is in focus right now FLSmidth (CPSE:FLS) has just completed the sale of its former corporate headquarters in Valby, Denmark, a previously flagged transaction that brings in net cash proceeds and an accounting gain in Q1 2026. See our latest analysis for FLSmidth. The DKK504.5 share price has climbed 4.4% over the last day and 8.9% over 90 days. The 1 year total shareholder return of 86.6% points to strong longer term momentum, even after a recent 4.4% 1 month share...

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities. See our latest analysis for Zealand Pharma. The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum...